OptiBiotix Health PLC

05 January 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

OptiBiotix obtains British Retail Consortium accreditation

One of the leading international food safety standards

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing unique science and human study-based compounds that modulate the microbiome to address metabolic syndrome and diabetes, systemic low-grade inflammation, obesity, cardiovascular disease, high cholesterol and to support healthy aging has achieved British Retail Consortium ('BRC') accreditation.

BRC was the first standard to meet the Global Food Safety Initiative ('GFSI') benchmark, which means it is accepted by many of the world's biggest retailers, such as Tesco and Walmart. The certification ensures customers have confidence in OptiBiotix's products and it allows the Company to do business with those retailers, manufacturers, ingredients companies and food service organisations who specify certification as part of their approval process (most large retailers and their suppliers). It incorporates food safety management systems and internationally accepted best practice to ensure the safety and quality of products and in doing so reduces the risk of recalls.

René Kamminga, C EO of O pti B i oti x Limited, c o mmented : "We are very pleased to announce our BRC accreditation which supports our commercial strategy of selling final product solutions to partners in the retail channel containing our science backed pro and prebiotic ingredients. I am particularly proud of our team which achieved this accreditation in a relatively short period of time."

For further information, please contact:

 OptiBiotix Health plc                      www.optibiotix.com 
 Stephen O'Hara, Chief Executive          Contact via Walbrook 
 Cenkos Securities plc (Broker)             Tel: 020 7397 8900 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 Walbrook PR Ltd                            Mob: 07876 741 001 
 Anna Dunphy 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 05, 2022 02:00 ET (07:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Giu 2022 a Lug 2022 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Lug 2021 a Lug 2022 Clicca qui per i Grafici di Optibiotix Health